Sun Pharma: FDA To Review SBLA For ILUMYA For Treatment Of Adults With Active Psoriatic Arthritis

The FDA has accepted for review Sun Pharmaceutical's supplemental BLA for ILUMYA for treatment of adults with active psoriatic arthritis, with a regulatory action date expected by October 29. Acceptance for review is a constructive regulatory step that raises the probability of label expansion and could act as a near-term catalyst for the stock ahead of the decision. Market impact is likely modest unless full approval is granted.

Analysis

The FDA has accepted for review Sun Pharmaceutical's supplemental BLA for ILUMYA for treatment of adults with active psoriatic arthritis, with a regulatory action date expected by October 29. Acceptance for review is a constructive regulatory step that raises the probability of label expansion and could act as a near-term catalyst for the stock ahead of the decision. Market impact is likely modest unless full approval is granted.